About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
2BB score and signals
BioMarin Pharmaceutical Inc.’s current 2BB score is 67 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 74 | High |
| Momentum | 73 | Improving |
| Financial strength | 69 | Strong |
| Quality | 100 | Very Strong |
| Risk | 30 | Low |
Company facts
| CEO | Alexander Hardy |
| Headquarters | San Rafael, California, United States |
| Founded | Mar 1997 |
| Employees | 3.22K |
| P/E ratio | 176.02 |
| 52-week range | $49.26 – $70.98 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-22 | — | 1.2324 | — | $1.15B |
| 2026-10-26 | — | 0.7839 | — | $1.05B |
| 2026-08-06 | — | 0.7016 | — | $945.45M |
| 2026-05-04 | 0.54 | 0.7656 | $766.21M | $771.12M |
Related companies
